Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas.

Mohanty SK, Smith SC, Chang E, Luthringer DJ, Gown AM, Aron M, Amin MB.

Am J Clin Pathol. 2014 Aug;142(2):173-83. doi: 10.1309/AJCPK1OV6IMNPFGL.

PMID:
25015857
2.

Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.

Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI.

Am J Surg Pathol. 2007 Aug;31(8):1246-55.

PMID:
17667550
4.

Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma.

Downes MR, Torlakovic EE, Aldaoud N, Zlotta AR, Evans AJ, van der Kwast TH.

J Clin Pathol. 2013 Sep;66(9):779-86. doi: 10.1136/jclinpath-2013-201586. Epub 2013 Jun 17.

PMID:
23775437
5.

Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.

Epstein JI, Egevad L, Humphrey PA, Montironi R; Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group.

Am J Surg Pathol. 2014 Aug;38(8):e6-e19. doi: 10.1097/PAS.0000000000000238.

PMID:
25029122
6.

Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall.

Gordetsky J, Epstein JI.

Am J Surg Pathol. 2014 Jul;38(7):941-5. doi: 10.1097/PAS.0000000000000178.

PMID:
24503758
7.

Poorly differentiated adenocarcinomas of prostate versus high-grade urothelial carcinoma of the bladder: a diagnostic dilemma with immunohistochemical evaluation of 2 cases.

Martínez-Rodríguez M, Ramos D, Soriano P, Subramaniam M, Navarro S, Llombart-Bosch A.

Int J Surg Pathol. 2007 Apr;15(2):213-8.

PMID:
17478786
8.

Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder.

Paner GP, Annaiah C, Gulmann C, Rao P, Ro JY, Hansel DE, Shen SS, Lopez-Beltran A, Aron M, Luthringer DJ, De Peralta-Venturina M, Cho Y, Amin MB.

Hum Pathol. 2014 Jul;45(7):1473-82. doi: 10.1016/j.humpath.2014.02.024. Epub 2014 Mar 14.

PMID:
24780825
9.

Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.

Lane Z, Hansel DE, Epstein JI.

Am J Surg Pathol. 2008 Sep;32(9):1322-6. doi: 10.1097/PAS.0b013e3181656ca0.

PMID:
18670358
10.

Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma.

Oh WJ, Chung AM, Kim JS, Han JH, Hong SH, Lee JY, Choi YJ.

J Pathol Transl Med. 2016 Sep;50(5):345-54. doi: 10.4132/jptm.2016.06.14. Epub 2016 Aug 7.

11.

Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.

Higgins JP, Kaygusuz G, Wang L, Montgomery K, Mason V, Zhu SX, Marinelli RJ, Presti JC Jr, van de Rijn M, Brooks JD.

Am J Surg Pathol. 2007 May;31(5):673-80.

PMID:
17460449
12.

Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma.

Bassily NH, Vallorosi CJ, Akdas G, Montie JE, Rubin MA.

Am J Clin Pathol. 2000 Mar;113(3):383-8.

PMID:
10705819
14.

Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung.

Gruver AM, Amin MB, Luthringer DJ, Westfall D, Arora K, Farver CF, Osunkoya AO, McKenney JK, Hansel DE.

Arch Pathol Lab Med. 2012 Nov;136(11):1339-46. doi: 10.5858/arpa.2011-0575-OA.

PMID:
23106579
15.

Immunohistochemical differential diagnosis between urothelial carcinoma and prostate adenocarcinoma among Egyptian patients.

Sakr SA, Abdel-Wahed MM, El-Sahra DG.

Biomed Pharmacother. 2014 Jul;68(6):685-92. doi: 10.1016/j.biopha.2014.08.003. Epub 2014 Aug 22.

PMID:
25194443
16.

Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma.

Mhawech P, Uchida T, Pelte MF.

Hum Pathol. 2002 Nov;33(11):1136-40.

PMID:
12454820
17.

Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.

Genega EM, Hutchinson B, Reuter VE, Gaudin PB.

Mod Pathol. 2000 Nov;13(11):1186-91.

18.
20.

Folate hydrolase (prostate-specific membrane [corrected] antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature.

Samplaski MK, Heston W, Elson P, Magi-Galluzzi C, Hansel DE.

Mod Pathol. 2011 Nov;24(11):1521-9. doi: 10.1038/modpathol.2011.112. Epub 2011 Jul 1. Erratum in: Mod Pathol. 2011 Nov;24(11):1531.

Supplemental Content

Support Center